Clinical Trial Update: SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating SH-1028 tablets versus placebo as adjuvant therapy in resected stage II-IIIB non-small cell lung cancer with EGFR sensitizing …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• SH-1028 (SH-1028)

Snippet

Sponsor: Nanjing Sanhome Pharmaceutical, Co., Ltd. | Conditions: Non-small Cell Lung Cancer | Phase 3 | Status: RECRUITING